In today’s research environment, pooling efforts and resources are among the most successful ways to advance knowledge and bring new, lifesaving products to market. Since 2008, the Society of Nuclear Medicine (SNM) has been assembling a roster of sites and organizations to develop new biomarkers.
Eli Lilly and Company is the most recent major company to join the SNM’s Clinical Trials Network. Currently more than 200 imaging sites and manufacturers in the United States, Europe, and Asia have enrolled in the network. The first clinical trial is slated for sometime this year.
In preparation for the trial, sites are in the process of being qualified. The network will improve standardization across multiple imaging sites within a single trial. Through strict adherence to common and appropriate protocols, the network will facilitate more consistent imaging data within multicenter trials—ultimately leading to personalized diagnostics and therapies for patients, according to the SNM.
(Source: Press Release)